院前心脏骤停患者到院时血糖水平与结局的关联:多中心队列研究
本研究为JAAM-OHCA登记数据的二次分析,纳入2014年6月至2019年12月日本成人(≥18岁)目击院外心脏骤停并转运至急诊科的患者11387例,按到院血糖分为<80、80–179、180–299、≥300 mg/dL四组。1个月生存率分别为1.3%、3.1%、7.0%、5.7%,良好神经结局率分别为0.4%、1.5%、3.3%、2.5%。多因素分析显示,与80–179 mg/dL组相比,180–299 mg/dL组1个月生存的OR为1.77(95%CI 1.34–2.31,p<0.001),良好神经结局的OR为1.52(95%CI 1.02–2.25,p=0.035)。立方样条回归模型提示结局最佳的血糖水平可能在200–250 mg/dL。
要点
- 到院血糖180–299 mg/dL组1个月生存率7.0%,高于80–179 mg/dL组的3.1%。
- 到院血糖180–299 mg/dL组良好神经结局率3.3%,高于80–179 mg/dL组的1.5%。
- 多因素分析:与80–179 mg/dL组相比,180–299 mg/dL组1个月生存OR 1.77(95%CI 1.34–2.31,p<0.001)。
- 多因素分析:与80–179 mg/dL组相比,180–299 mg/dL组良好神经结局OR 1.52(95%CI 1.02–2.25,p=0.035)。
- 立方样条回归模型提示,结局最佳的到院血糖水平可能在200–250 mg/dL。
适用人群与场景
- 成人(≥18岁)目击院外心脏骤停并转运至急诊科的患者,数据来自JAAM-OHCA登记库,纳入时间为2014年6月至2019年12月。
诊断标准与关键阈值
- 到院血糖分组:<80 mg/dL、80–179 mg/dL、180–299 mg/dL、≥300 mg/dL。
- 良好神经结局定义为1个月时Glasgow-Pittsburgh Cerebral Performance Category评分为1或2。
研究设计与关键结果
- 研究类型:JAAM-OHCA登记数据的二次分析,多中心队列研究,纳入11387例患者。
- 1个月生存率:<80 mg/dL组1.3%、80–179 mg/dL组3.1%、180–299 mg/dL组7.0%、≥300 mg/dL组5.7%。
- 1个月良好神经结局率:<80 mg/dL组0.4%、80–179 mg/dL组1.5%、180–299 mg/dL组3.3%、≥300 mg/dL组2.5%。
- 多因素分析:与80–179 mg/dL组相比,180–299 mg/dL组1个月生存OR 1.77(95%CI 1.34–2.31,p<0.001),良好神经结局OR 1.52(95%CI 1.02–2.25,p=0.035)。
- 立方样条回归模型提示,结局最佳的到院血糖水平可能在200–250 mg/dL。
证据类型、等级与局限
- 证据类型:多中心队列研究(基于登记数据的二次分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在院外心脏骤停患者中,到院血糖180–299 mg/dL与1个月生存和良好神经结局显著相关(相较于80–179 mg/dL)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: This study aimed to investigate the association between blood glucose levels on arrival at the hospital and 1-month survival and favorable neurological outcomes in patients with OHCA using a large Japanese dataset.
METHODS: This study was a secondary analysis of data from the JAAM-OHCA Registry. Adult (≥18 years) patients with witnessed OHCA transported to emergency departments and registered in the database from June 2014 to December 2019 were included in the study. The primary and secondary endpoints were 1-month survival and 1-month favorable neurological outcomes (Glasgow-Pittsburgh Cerebral Performance Category score 1 or 2), respectively. Patients were categorized into the following four groups based on blood glucose levels on arrival at the hospital: <80 mg/dL, 80-179 mg/dL, 180-299 mg/dL, and ≥300 mg/dL.
RESULTS: This study included 11,387 patients. Survival rates were 1.3%, 3.1%, 7.0%, and 5.7% in the <80 mg/dL, 80-179 mg/dL, 180-299 mg/dL, and ≥ 300 mg/dL blood glucose groups, respectively. The rates of favorable neurological outcomes in each group were 0.4%, 1.5%, 3.3%, and 2.5%, respectively. Multivariable analysis showed that 180-299 mg/dL glucose was significantly associated with 1-month survival and favorable neurological outcomes compared with 80-179 mg/dL glucose (odds ratio [OR], 1.77; 95% confidence interval [CI], 1.34-2.31; p < 0.001 and OR, 1.52; 95 % Cl, 1.02-2.25; p = 0.035, respectively). In this study, blood glucose levels with the best outcomes likely ranged from 200 to 250 mg/dL based on the cubic spline regression model.
CONCLUSIONS: Blood glucose level of 180-299 mg/dL on arrival at the hospital was significantly associated with 1-month survival and favorable neurological outcomes compared to blood glucose level of 80-179 mg/dL in patients with OHCA.
参考来源
- Taira T, Inoue A, Kuroda Y, et al. The association between blood glucose levels on arrival at the hospital and patient outcomes after out-of-hospital cardiac arrest: A multicenter cohort study. Am J Emerg Med. 2023. PMID: 38101226. doi:10.1016/j.ajem.2023.12.004
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。